findmyKOL
Clinical trialNCT04990102RecruitingPhase 1/PHASE2Interventional

Phase IB/II of CPX-351 for Relapse Prevention in AML

SponsorGeorgetown UniversityEnrollment24Acute Myeloid Leukemia (AML) in Remission
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia, United States

    Kimberley Doucette, MD
    Recruiting
  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey, United States

    James McCloskey, MD
    Recruiting
  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

    Catherine Lai, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CPX-351
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
22 May 2023
Primary completion
31 Dec 2026
Completion
31 Dec 2026
Last update posted
23 Mar 2026
Registered enrollment
24
Registry id
NCT04990102
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.